TILT Biotherapeutics Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 25

Employees

  • Latest Deal Type
  • Crowdfunding

  • Latest Deal Amount
  • $12.9M

  • Investors
  • 12

TILT Biotherapeutics General Information

Description

Developer of a biotechnology platform intended to develop oncolytic immunotherapies that will modify the tumor microenvironment and eliminate its ability to suppress immune responses to cancer. The company's platform involves the utilization of oncolytic viruses to enhance tumor cell therapy and will be used in tumor-infiltrating lymphocytes, chimeric antigen receptors and checkpoints, enabling researchers to inhibit antibody therapy for solid tumors to achieve similar results.

Contact Information

Website
www.tiltbio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Tukholmankatu 8 B
  • Biomedicum 2B, (2nd floor)
  • 00290 Helsinki
  • Finland
+358 09
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Tukholmankatu 8 B
  • Biomedicum 2B, (2nd floor)
  • 00290 Helsinki
  • Finland
+358 09

TILT Biotherapeutics Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

TILT Biotherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Equity Crowdfunding 27-Jun-2024 $12.9M Completed Clinical Trials - Phase 2
8. Later Stage VC (Series A) 07-Feb-2023 Completed Clinical Trials - Phase 2
7. Later Stage VC 16-Jun-2020 Completed Clinical Trials - Phase 2
6. Equity Crowdfunding 02-Apr-2020 Completed Clinical Trials - Phase 2
5. Later Stage VC (Series A) 04-Jun-2018 Cancelled Clinical Trials - Phase 2
4. Grant 04-Jun-2018 Completed Clinical Trials - Phase 2
3. Seed Round 14-Dec-2016 Completed Pre-Clinical Trials
2. Seed Round 30-Sep-2015 $3.48M $5.32M Completed Pre-Clinical Trials
1. Seed Round 01-Aug-2013 $1.83M $1.83M Completed Pre-Clinical Trials
To view TILT Biotherapeutics’s complete valuation and funding history, request access »

TILT Biotherapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Ordinary
Ordinary
Series A 212,713 $16.94 $16.94 1x $16.94 1.15%
Series A 202,090 $4.83 $4.83 1x $4.83 1.09%
To view TILT Biotherapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

TILT Biotherapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a biotechnology platform intended to develop oncolytic immunotherapies that will modify the tumor microenvi
Drug Discovery
Helsinki, Finland
25 As of 2024

Cambridge, MA

Santa Monica, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

TILT Biotherapeutics Competitors (36)

One of TILT Biotherapeutics’s 36 competitors is Aurora Biopharma, a Angel-Backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aurora Biopharma Angel-Backed Cambridge, MA
Kite Pharma Formerly VC-backed Santa Monica, CA
NexImmune Formerly VC-backed Gaithersburg, MD
TScan Therapeutics Formerly VC-backed Waltham, MA
Oncorus Formerly VC-backed Andover, MA
You’re viewing 5 of 36 competitors. Get the full list »

TILT Biotherapeutics Patents

TILT Biotherapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022358966-A1 An oncolytic virus vector coding for interleukin-7 (il-7) polypeptide Pending 04-Oct-2021
CA-3233797-A1 An oncolytic virus vector coding for interleukin-7 (il-7) polypeptide Pending 04-Oct-2021
US-20240398986-A1 An oncolytic virus vector coding for interleukin-7 (il-7) polypeptide Pending 04-Oct-2021
EP-4412640-A1 An oncolytic virus vector coding for interleukin-7 (il-7) polypeptide Pending 04-Oct-2021
JP-2023505925-A Oncolytic viral vectors encoding variant interleukin-2 (vil-2) polypeptides Pending 11-Oct-2019 C12N15/861
To view TILT Biotherapeutics’s complete patent history, request access »

TILT Biotherapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

TILT Biotherapeutics Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
European Innovation Council Fund Venture Capital Minority
Loipposet Venture Capital Minority
Stephen Industries Venture Capital Minority
Tesi Limited Partner Minority
Angel (individual) Minority
You’re viewing 5 of 12 investors. Get the full list »

TILT Biotherapeutics FAQs

  • When was TILT Biotherapeutics founded?

    TILT Biotherapeutics was founded in 2013.

  • Where is TILT Biotherapeutics headquartered?

    TILT Biotherapeutics is headquartered in Helsinki, Finland.

  • What is the size of TILT Biotherapeutics?

    TILT Biotherapeutics has 25 total employees.

  • What industry is TILT Biotherapeutics in?

    TILT Biotherapeutics’s primary industry is Drug Discovery.

  • Is TILT Biotherapeutics a private or public company?

    TILT Biotherapeutics is a Private company.

  • What is the current valuation of TILT Biotherapeutics?

    The current valuation of TILT Biotherapeutics is .

  • What is TILT Biotherapeutics’s current revenue?

    The current revenue for TILT Biotherapeutics is .

  • How much funding has TILT Biotherapeutics raised over time?

    TILT Biotherapeutics has raised $56.5M.

  • Who are TILT Biotherapeutics’s investors?

    European Innovation Council Fund, Loipposet, Stephen Industries, Tesi, and are 5 of 12 investors who have invested in TILT Biotherapeutics.

  • Who are TILT Biotherapeutics’s competitors?

    Aurora Biopharma, Kite Pharma, NexImmune, TScan Therapeutics, and Oncorus are some of the 36 competitors of TILT Biotherapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »